3Collins MM, Meigs JB, Barry MJ, et al, Prevalence and correlates of prostatitis in the health professionals follow -up study cohort. J Urol,2002; 167:1363 -6.
4Kohnen PW, Drach GW. Patterns of inflammation in prostatic hyperpIasia: a histologic and bacteriologic study, J Urol. 1979; 121 (6) :755 -60.
5Blumenfeld W, Tueei S, Narayan P. Incidental lymphocytic prostatitis. Selective involvement with nonmalignant glands. Am J Surg Pathol, 1992, 16 ( 1 O) :975 - 81.
6Bedalov G, Vuckovic 1, Fridrih S, et al. Prostatitis in benign prostatic hyperplasia: a histological, bacteriological and clinical study. Acta Med Croatica, 1994,48(3) :105 -9.
7Gerstenbluth RE, Steftel AD, MaeLennan GT, et al. Distribution of chronic prostatitis in radical prostatectomy specimens with up - regulation of Bcl-2 in areas of inflammation. J Urol, 2002, 167(5) :2267-70.
8Nickel JC, Downey J, Young 1, et al. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia . BJU Int, 1999;84:976 - 81.
9Krieger JN, Nyberg L Jr, Nickle JC. NIH consensus definition and classification of prostatitis. JAMA, 1999, 282 ( 3 ) ; 236 - 7.
10Anim JT, Udo C, John B. Charactefisation of inflammatory cells in benign prostatic hyperplasia. Acta Histochem. 1998, 100(4) :439 -49.
6Plotnikov EY, Pulkova NV, Pevzner IB, et al. Inflammatory pre-conditioning of mesenchymal multipotent stromal cells im- proves their immunomodulatory potency in acute pyelonephri- tis in rats[J]. Cytotherapy,2013,15(6) :679-689.
7Spoelstra SK, Waldinger MD, Nijhuis ER, et al. A Woman with restless genital syndrome: a difficult-to-treat condition [J]. Ned Tijdschr Geneeskd, 2013, 157(16): A5805.
9Wang J, Zurawski TH, Bodeker M, etal. Longer-acting and highly potent chimaerie inhibitors of excessive exoeytosis crea- ted with domains from botulinum neurotoxin A and B[J]. Bio- chem J,2012,444(1) : 59 -67.
